GlassScriptPhysician profile
Wendell B Phillips
NPI 1598757114
$15,987.42
in general payments reported to CMS, 2019-2025
49 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 94% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,239 · 2020: $1,166 · 2021: $2,248 · 2022: $1,582 · 2023: $1,881 · 2024: $1,413 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,508 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,507.80 |
| Education | $244.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,830.38 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Novo Nordisk INC | $2,106.60 | 2019-2025 | Wegovy, Ozempic |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Abbvie INC. | $1,175.46 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $745.23 | 2023-2025 | Caplyta |
| Amgen INC. | $506.83 | 2019-2025 | Tezspire, Repatha |
| Lilly USA, LLC | $505.01 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $400.99 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $376.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $372.05 | 2019-2020 | |
| Amarin Pharma, INC. | $311.93 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $264.67 | 2019-2025 | Zoryve |
| Genentech USA, INC. | $246.10 | 2019 | |
| Glaxosmithkline, LLC. | $232.62 | 2019-2020 | |
| Smith+Nephew, INC. | $230.15 | 2019 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.